Glucotrack Touts Positive Study Data for Implantable Glucose Monitor Tech

Glucotrack Inc. is sharing positive results for a feasibility study it completed for an implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes.
 
The study’s primary goal was to demonstrate that Glucotrack’s CGM sensor design could reliably report glucose measurements for two years post-implant. Laboratory bench testing confirmed that a minimum two-year implant longevity is highly probable with the current sensor design. The implant longevity was independently verified by a third-party using sensor parameters to simulate sensor performance over time.
 
Given the study’s positive results, the company is now preparing for long-term animal studies, which are expected to begin later this year.
 
“We are pleased to have met our goal to confidently project a long-term sensor life that is at least four times longer than what is currently available for an implantable CGM, without the requirement for external wearables or frequent calibrations.” Glucotrack CEO Paul Goode said. “We look forward to the animal study as the next development step of this exciting technology that can help improve the lives of so many.”
 
Glucotrack is committed to commercializing an implantable CGM with long-term sensor life with no requirement for any additional wearable component, and a once-only calibration. The company believes these will be key differentiators as compared to other continuous glucose monitors, either currently on the market or known to be in development.
 
Glucotrack Inc. (formerly known as Integrity Applications Inc.) designs, develops, and commercializes technologies for people with diabetes and prediabetes. The company’s initial product, Glucotrack, is a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices.